← Back to Search

Anti-cancer drug

PTX-200 and cytarabine for Acute Leukemia

Phase 1 & 2
Waitlist Available
Led By Jeffrey Lancet, MD
Research Sponsored by Prescient Therapeutics, Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Summary

A phase I-II open label study of PTX-200 in combination with cytarabine in the treatment of relapsed or refractory acute leukemia.

Eligible Conditions
  • Acute Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Treatment-related Adverse Events
Secondary study objectives
Phospho-Akt (pAkt) expression within CD34+ leukemic blasts

Trial Design

1Treatment groups
Experimental Treatment
Group I: PTX-200 and cytarabineExperimental Treatment2 Interventions
PTX-200 administered intravenously over 1 hour Phase I: 4 dose levels: 25 to 55 mg/m2 (with reduction to 15 mg/m2 if needed. Phase II: maximum tolerated dose. given as a 1 hour infusion Cytarabine administered by continuous infusion at a dose of 400 mg/m2/day for 4 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PTX-200
2016
Completed Phase 2
~40
Cytarabine
FDA approved

Find a Location

Who is running the clinical trial?

Prescient Therapeutics, Ltd.Lead Sponsor
5 Previous Clinical Trials
112 Total Patients Enrolled
Jeffrey Lancet, MDPrincipal InvestigatorMoffitt Cancer Center
~4 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top